プロモーションスケジュール Actinogen Medical Limited
詳細なスケジュール
簡易グラフ
会社について Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. さらに詳しくIndustry | Biotechnology |
---|---|
Sector | Health Care |
Валюта | usd |
Валюта отчета | aud |
Сайт | https://actinogen.com.au |
Цена ао | 0.025 |
1日あたりの価格変動: | 0% (0.025) |
---|---|
週ごとの価格変動: | 0% (0.025) |
月ごとの料金変更: | 0% (0.025) |
3ヶ月間の価格変動: | +25% (0.02) |
半年間の価格変動: | +66.67% (0.015) |
年間の価格変動: | +66.67% (0.015) |
3年間の価格推移: | +4.17% (0.024) |
5年間の価格推移: | -13.79% (0.029) |
年初からの価格変動: | +25% (0.02) |
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
スーパーバイザー | 役職 | 支払い | 生年 |
---|---|---|---|
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. | MD, CEO & Director | 1959 (66 年) | |
Mr. William Edward Souter BCom, IPAA, LLB (Adel) | Chief Financial Officer | ||
Dr. Dana C. Hilt M.D. | Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 1953 (72 年) | |
Mr. Michael Roberts | Head of Investor Relations & Corporate Communications | ||
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Head of Clinical Pharmacology & Lead Physician and Depression | ||
Dr. Fujun Li Ph.D. | Head of Manufacturing | ||
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary | 1963 (62 年) |
住所: Australia, Sydney, 109 Pitt Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://actinogen.com.au
Webサイト: https://actinogen.com.au